BiotechTube

efatutazone

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma

Trial Timeline

Feb 11, 2015 → May 1, 2023

NCT ID
NCT02249949

About efatutazone

efatutazone is a phase 2 stage product being developed by Daiichi Sankyo for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02249949. Target conditions include Liposarcoma.

What happened to similar drugs?

0 of 1 similar drugs in Liposarcoma were approved

Approved (0) Terminated (0) Active (1)
🔄Abemaciclib + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02249949Phase 2Completed

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
44
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
35
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
35
HDM201 + LEE011NovartisPhase 1
29
pazopanibNovartisPhase 2
35
PF-07220060 + MidazolamPfizerPhase 2
39
Sunitinib Malate (SU011248)PfizerPhase 2
35
CabazitaxelSanofiPhase 2
35
INCMGA00012 + PalbociclibIncytePhase 2
36
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
28
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
11